18F-FDG PET/CT influences management in patients with known or suspected pancreatic cancer

Internal Medicine Journal

Volumn 41, Issue 11, 2011, Pages 776-783

  Barber, T W ^a   Kalff, V ^a   Cherk, M H ^a,b   Yap, K S K ^a   Evans, P ^c   Kelly, M J ^a  

^a PET Centre   (Australia)

^b Department of Medical Oncology ^*  (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Management impact; Pancreatic cancer; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONVENTIONAL STAGING INVESTIGATION; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; MALE; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; DISEASE MANAGEMENT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 81255176128     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02257.x     Document Type: Article

References (21)

1. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005; 128: 1626-41.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-57.
3. Schmidt CM, Glant J, Winter JM, Kennard J, Dixon J, Zhao Q etal. Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 2007; 142: 572-8; discussion 78-80.
4. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
5. Koyama K, Okamura T, Kawabe J, Nakata B, Chung KH, Ochi H etal. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001; 15: 217-24.
6. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD etal. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40: 1784-91.
7. Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Pedrazzoli S. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 2005; 9: 22-8; discussion 28-9.
8. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW etal. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999; 229: 729-37; discussion 37-8.
9. Franke C, Klapdor R, Meyerhoff K, Schauman M. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999; 19: 2437-42.
10. Kalra MK, Blake MA, Saini S. Role of dual PET/CT scanning in abdominal malignancies. Cancer Imaging 2004; 4: 121-3.
11. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT etal. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008; 15: 2465-71.
12. Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC etal. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242: 235-43.
13. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E etal. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 2008; 49: 1928-35.
14. Chatterton BE, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B etal. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009; 36: 354-61.
15. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 2006; 36: 248-56.
16. Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC etal. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008; 49: 1408-13.
17. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B etal. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997; 24: 678-82.
18. Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ etal. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20: 109-16.
19. Frohlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999; 40: 250-5.
20. Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J etal. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging 2008; 33: 87-93.
21. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007; 244: 566-74.